Clinical Trial

Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.

Study acronym: DOBL
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 11, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions. The role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement in overall survival and progression free survival with combined modality treatment. The doses of radiation used in these trials are heterogeneous ranging from 30-55 Gray(Gy). There is uncertainty about the optimal dose of radiation needed in aggressive lymphomas. A dose response phenomenon is known in Non- Hodgkin's Lymphoma. Late effects of higher dose radiation in the form of higher risk of stroke, myocardial infarction, thyroid abnormalities and secondary breast cancer are being increasingly identified. Hence it is essential to optimize the dose of radiotherapy for lower toxicity without compromising on efficacy.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2016-11-15; most recent amendment 2025-04-08.
Status change: Not Yet Recruiting → Recruiting 2016-12-01
Trial Details
NCT Number NCT02964858
Lead Sponsor Tata Memorial Hospital
Conditions NonHodgkin Lymphoma
Enrollment 840 participants
Start Date 2016-11
Primary Completion 2026-03 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2025-04-11